What is your approach to HR+ unilateral IDC with positive bilateral axillary nodes?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

For a patient with ER+, HER2-low leptomeningeal disease, but no other sites of metastatic disease, what treatments would you consider after trastuzumab deruxtecan?

When making treatment decisions, how do you deal with conflicting results on HER2 measurement via IHC, FISH, and Oncotype Dx HER2 expression levels?

1 Answers

In which scenarios would you consider adjuvant CDK4/6 inhibitor use if there is only one ipsilateral axillary lymph node positive for microscopic disease?

1 Answers

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

What is your approach to HR+ unilateral IDC with positive bilateral axillary nodes? ​

What is your approach to HR+ unilateral IDC with positive bilateral axillary nodes?